Mononitrate Isosorbide as an Adjunctive Therapy in Schizophrenia

Guimarães, Tiago M; Guimarães, Marcelo de Paiva; Oliveira, Ícaro A.F.; Leoni, Renata Ferranti; Santos, Antônio Carlos dos; Dursun, Serdar; Crippa, José Alexandre S; Bressan, Rodrigo; Machado‐de‐Sousa, João Paulo; Lacerda, Acioly Luiz Tavares de; Hallak, Jaime Eduardo Cecílio

doi:10.1097/jcp.0000000000001388

Cited by 3 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endogenous Inhibition AG Schizophrenia [27] L-NOARG Schizophrenia [26] AG Depression [24] 7-NI Depression [22] Stimulation Heme-lysinate Depression [32] External External stimuliresponsive gasotransmitter prodrugs SNP Depression [34] SNP Schizophrenia [35] Molsidomine Depression [46] Molsidomine Schizophrenia [47] DETA/NONOate Depression [52] CORM-2 Depression [53] CORM-3 Depression [55] CO-rich saline or CO gas Depression [56] NaHS Depression [58] Na 2 S Depression [64] DADS Depression [67] Hydrogen-Rich Water Depression [71] Nano-gas carrier CORM-2-SLN Depression [54] These gas-related drugs can affect the development of depression and schizophrenia by either stimulating the production of gas or inhibiting its production. thus reduces cGMP production.…”

Section: Strategymentioning

confidence: 99%

“…SNP is a fast-acting vasodilator that increases cerebral perfusion and helps to treat the typical symptoms of cerebral underperfusion in patients with schizophrenia. [35] According to a body of evidence, [36,37] SNP may correct schizophrenia-like symptoms caused by the pharmacological effects of the glutamatergic and DAergic systems. The NMDA-nNOS-cGMP pathway is impaired in schizophrenia, and SNP treats schizophrenia by complementing the NMDA-nNOS-cGMP pathway.…”

Section: External Gas Delivery Strategymentioning

confidence: 99%

See 1 more Smart Citation

Gas therapy strategies for depression and schizophrenia: A review

Tao,

Zhu,

Liu

et al. 2023

Medicine

View full text Add to dashboard Cite

Depression and schizophrenia are 2 serious mental disorders. Their effective treatment is an urgent medical and social problem at present. Drug treatment is the basic measure to improve mental disorders, especially serious mental disorders. However, the side effects of traditional antipsychotic drugs cannot be avoided. Surprisingly, in recent years, it has been found that nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H2S) and hydrogen (H2) can regulate corresponding signal pathways to treat mental diseases in animal models. More importantly, as gas signal molecules, they will not bring toxicity and side effects after metabolism. Therefore, in this review, we analyzed the effects of gas on depression and schizophrenia through endogenous gas generation and external gas delivery strategies in some animal models. Endogenous gas generation strategy: summarized the therapeutic mechanism of gas signaling molecules on depression and schizophrenia, and listed the main ways to inhibit or stimulate gas generation. External gas delivery strategy: The common external stimuli-responsive gasotransmitter prodrugs and some study of these prodrugs in the treatment of depression and schizophrenia are summarized. We also analyzed the prospects of nano-gas carrier in the treatment of depression and schizophrenia. Through this review, we hope to provide guidance for treating depression and schizophrenia by regulating relevant gas signal pathways, and provide reference for developing safe and effective drugs for treating mental disorders by summarizing exogenous gas drugs.

show abstract

Section: Strategymentioning

confidence: 99%

Section: External Gas Delivery Strategymentioning

confidence: 99%

Gas therapy strategies for depression and schizophrenia: A review

Tao,

Zhu,

Liu

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…In a randomized, double-blind, placebo-controlled preliminary trial performed in 24 schizophrenics under medication, repeated treatment with ISMN exerted a beneficial effect on positive symptoms and functioning. In spite of it, important limitations characterize this interesting study including the sample size, the absence of healthy controls and the investigation of a single dose of ISMN [ 66 ]. Future research is mandatory to evaluate the efficacy of this NO donor as a potential antipsychotic agent.…”

Section: Snp and Schizophreniamentioning

confidence: 99%

The Nitric Oxide (NO) Donor Sodium Nitroprusside (SNP) and Its Potential for the Schizophrenia Therapy: Lights and Shadows

Zoupa

Pitsikas

2021

Molecules

View full text Add to dashboard Cite

Schizophrenia is a severe psychiatric disorder affecting up to 1% of the worldwide population. Available therapy presents different limits comprising lack of efficiency in attenuating negative symptoms and cognitive deficits, typical features of schizophrenia and severe side effects. There is pressing requirement, therefore, to develop novel neuroleptics with higher efficacy and safety. Nitric oxide (NO), an intra- and inter-cellular messenger in the brain, appears to be implicated in the pathogenesis of schizophrenia. In particular, underproduction of this gaseous molecule is associated to this mental disease. The latter suggests that increment of nitrergic activity might be of utility for the medication of schizophrenia. Based on the above, molecules able to enhance NO production, as are NO donors, might represent a class of compounds candidates. Sodium nitroprusside (SNP) is a NO donor and is proposed as a promising novel compound for the treatment of schizophrenia. In the present review, we intended to critically assess advances in research of SNP for the therapy of schizophrenia and discuss its potential superiority over currently used neuroleptics.

show abstract